Bruker (BRKR) Hisse Özeti
Bruker Corporation, iştirakleriyle birlikte bilimsel aletler, analitik ve teşhis çözümleri geliştirmekte, üretmekte ve dağıtmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 5/6 |
| Gelecekteki Büyüme | 3/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 3/6 |
| Temettüler | 0/6 |
BRKR Community Fair Values
Create NarrativeSee what 29 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Bruker Corporation Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$57.02 |
| 52 Haftanın En Yüksek Seviyesi | US$65.30 |
| 52 Haftanın En Düşük Seviyesi | US$28.53 |
| Beta | 1.28 |
| 1 Aylık Değişim | -5.06% |
| 3 Aylık Değişim | 30.03% |
| 1 Yıllık Değişim | 76.21% |
| 3 Yıllık Değişim | -15.83% |
| 5 Yıllık Değişim | -31.33% |
| Halka arzdan bu yana değişim | 147.24% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Aug 07
BRKR: Premium Multiple Will Face Earnings Risk After Recent Guidance Miss
The updated analyst price target for Bruker moves from an implied fair value of about $35.00 to approximately $42.30 as analysts balance slightly higher assumed profit margins and P/E expectations, more cautious revenue growth forecasts, and an unchanged mix of Neutral, Hold, Buy, Overweight and Peer Perform ratings across recent research. Analyst Commentary Recent Street research on Bruker shows a mix of enthusiasm and caution, with several firms adjusting price targets and ratings as they reassess valuation, growth assumptions, and execution risks ahead of earnings updates.Seeking Alpha • Aug 05
Weak Growth In Its Primary Market Continues To Weigh Heavily On Bruker Shares
Summary Bruker faces ongoing headwinds from weak academic/government funding that has compressed growth despite strong semiconductor and energy research markets. Q2 delivered strong order growth and margin improvement, but revenue missed expectations and near-term guidance is soft, raising execution risk for FY targets. BRKR's high exposure to academic/government end markets remains a structural challenge, but growth in biopharma, diagnostics, and semiconductor segments offers long-term upside. Valuation appears modestly attractive with potential 30%+ upside, yet tepid organic growth and guidance uncertainty temper immediate buy conviction. Read the full article on Seeking AlphaRecent updates
Anlatı Güncellemesi • Aug 07
BRKR: Premium Multiple Will Face Earnings Risk After Recent Guidance Miss
The updated analyst price target for Bruker moves from an implied fair value of about $35.00 to approximately $42.30 as analysts balance slightly higher assumed profit margins and P/E expectations, more cautious revenue growth forecasts, and an unchanged mix of Neutral, Hold, Buy, Overweight and Peer Perform ratings across recent research. Analyst Commentary Recent Street research on Bruker shows a mix of enthusiasm and caution, with several firms adjusting price targets and ratings as they reassess valuation, growth assumptions, and execution risks ahead of earnings updates.Seeking Alpha • Aug 05
Weak Growth In Its Primary Market Continues To Weigh Heavily On Bruker Shares
Summary Bruker faces ongoing headwinds from weak academic/government funding that has compressed growth despite strong semiconductor and energy research markets. Q2 delivered strong order growth and margin improvement, but revenue missed expectations and near-term guidance is soft, raising execution risk for FY targets. BRKR's high exposure to academic/government end markets remains a structural challenge, but growth in biopharma, diagnostics, and semiconductor segments offers long-term upside. Valuation appears modestly attractive with potential 30%+ upside, yet tepid organic growth and guidance uncertainty temper immediate buy conviction. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jul 24
BRKR: Infection Detection Expansion Will Meet Rich Tools Sector Expectations
Bruker’s updated analyst price target of $59.75, up from $56, reflects a series of target increases into the $60 to $70 range as analysts recalibrate their models for life science and diagnostic tools stocks and incorporate what they view as reasonable earnings expectations along with improving sentiment toward the group. Analyst Commentary Recent research updates on Bruker show a wide range of price targets clustered between US$60 and US$70, with most analysts adjusting their models for the life science and diagnostic tools sector ahead of upcoming earnings reports.Anlatı Güncellemesi • Jul 10
BRKR: Diagnostics Portfolio Momentum Will Counter Valuation And Execution Uncertainty
The analyst fair value estimate for Bruker has been raised from $53.25 to $56.00 after analysts responded to a series of higher Street price targets and updated models across diagnostics and life sciences tools coverage. Analyst Commentary Recent Street research on Bruker shows a mix of optimism and caution, with several firms updating price targets and ratings as they refresh models across diagnostics and life sciences tools coverage.Anlatı Güncellemesi • Jun 26
BRKR: Rich Multiple And Execution Risks Will Pressure Earnings Power Into 2026
Bruker’s analyst fair value estimate has been revised from $36.80 to $35.00 as analysts weigh a richer valuation, even as several recent price target increases in the $60 to $65 range cite updated models and improving sentiment toward life science and diagnostic tools stocks. Analyst Commentary Recent Street commentary on Bruker shows a clear divide between optimistic targets and more cautious views that question how much upside is left at current prices.Anlatı Güncellemesi • Jun 11
BRKR: Semiconductor And Diagnostics Momentum Will Balance Helium And Execution Risks
The updated analyst price target for Bruker has moved from an implied fair value of $49.15 to $53.25, reflecting recent target hikes into the $65 range by several firms as analysts incorporate refreshed models, sector sentiment, and valuation concerns into their views. Analyst Commentary Recent research updates show a mix of optimism and caution around Bruker, with price targets clustering around US$65 alongside more neutral stances that focus on valuation and operating risks.Anlatı Güncellemesi • May 28
BRKR: Rising Helium Costs Will Constrain Earnings Power Into 2026
Analysts have lifted their average price target on Bruker by about $1.80, citing updated assumptions that include a slightly lower discount rate, modestly higher revenue growth and profit margin expectations, and a lower future P/E multiple. Analyst Commentary Recent Street research on Bruker reflects a mix of optimism on long term prospects and concern about near term risks.Anlatı Güncellemesi • May 14
BRKR: 2026 Earnings Delivery Will Outweigh Helium Cost Headwinds
Bruker's updated analyst price target has shifted to $49.15 from $47.86, as analysts factor in moderate adjustments to discount rates, revenue growth, profit margins and expected future P/E multiples, following a mix of recent target raises and cuts across the Street. Analyst Commentary Recent research on Bruker reflects a split view, with some analysts lifting price targets and others trimming them, as they reassess valuation, execution risk and potential headwinds in key input costs.Anlatı Güncellemesi • Apr 29
BRKR: Helium Cost Pressures And Margin Execution Will Shape 2026 Path
Analysts have trimmed their average price targets on Bruker by several dollars to reflect helium cost headwinds, recent margin pressure and lower valuation multiples, while underlying long term revenue growth and profit margin assumptions remain broadly consistent. Analyst Commentary Bearish analysts have been resetting expectations on Bruker, with several firms cutting price targets by mid single digit to low double digit dollar amounts.Anlatı Güncellemesi • Apr 15
BRKR: Rising Helium Costs Will Pressure Margins And Test 2026 Earnings
Analysts have reduced their Bruker price targets by mid single digit dollar amounts, citing lower margin expectations, helium related cost headwinds and revised sector multiples. These factors, in turn, feed into a higher implied future P/E and modest adjustments to growth and discount rate assumptions.Anlatı Güncellemesi • Apr 01
BRKR: 2026 Earnings Framework And Helium Risk Will Shape Future P/E
Bruker's updated analyst price target edges lower to about $48 per share, as analysts trim fair value and future P/E assumptions while factoring in helium cost risks and recent price target resets across the coverage group. Analyst Commentary Recent Street research on Bruker reflects a mix of optimism around long term growth targets and caution around nearer term execution, margins, and input cost risks.Anlatı Güncellemesi • Mar 18
BRKR: 2026 Earnings Framework And Spatial Biology Expansion Will Support Higher P/E
Analysts have reduced the average Bruker price target to about $48, citing helium cost headwinds, a Q4 margin miss and lower sector valuation multiples, while noting that longer term earnings expectations remain in place. Analyst Commentary Research commentary on Bruker highlights a mix of optimism on long term earnings power and caution around near term execution risks and input costs, particularly helium.Anlatı Güncellemesi • Mar 03
BRKR: Reset Margins And 2026 Outlook Will Support Higher Forward P/E
Analysts have reset their view on Bruker, trimming the target to about $48 from about $54 as they factor in recent Q4 margin pressure, higher assumed discount rates and lower profit margin expectations. This comes even as revenue growth forecasts and future P/E assumptions move higher and Street research shows a mix of price target cuts and raises across firms.Anlatı Güncellemesi • Feb 17
BRKR: Future Earnings Reset Will Test 2026 Margin Ramp Assumptions
Analysts have trimmed their fair value estimate for Bruker to $35 from $38, reflecting lower applied multiples on future earnings targets after recent price target cuts across several firms, even as updated assumptions factor in changes to revenue growth and profit margins. Analyst Commentary Recent Street research around Bruker has turned more mixed, with several bearish analysts cutting price targets after the latest quarterly update, even as some firms maintain positive ratings or modestly higher targets.Analiz Makalesi • Feb 15
Analysts Have Been Trimming Their Bruker Corporation (NASDAQ:BRKR) Price Target After Its Latest Report
It's been a sad week for Bruker Corporation ( NASDAQ:BRKR ), who've watched their investment drop 13% to US$36.51 in...Anlatı Güncellemesi • Feb 03
BRKR: Q4 Setup And BEST Agreements Will Support Higher Forward P/E Multiple
Analysts have lifted their price targets on Bruker by amounts such as $5, $13 and to $53, citing updated views on the life science tools sector and Q4 setups. This feeds into our slightly higher fair value estimate and revised assumptions for discount rate, revenue growth, profit margin and future P/E.Anlatı Güncellemesi • Jan 20
BRKR: Constructive Bookings And Rating Upgrade Will Support Higher Forward P E Multiple
Analysts have lifted their Bruker price target to about $54 from about $52, citing slightly higher fair value estimates and modest adjustments to the discount rate, margin assumptions, and future P/E expectations. These changes are supported by a series of recent target hikes and an upgrade to Hold in the life science tools peer group.Anlatı Güncellemesi • Jan 06
BRKR: Constructive Bookings And Rating Upgrade Will Shape Balanced Forward Expectations
Analysts have raised their price target on Bruker by about US$0.57 to around US$52.36, reflecting updated views that factor in steadier bookings and the recent shift from Sell to Hold in Street ratings. Analyst Commentary Recent Street research on Bruker reflects a more balanced stance, with some analysts turning less negative while still highlighting execution risks and guidance concerns.Anlatı Güncellemesi • Dec 17
BRKR: Constructive Bookings And Rating Upgrade Will Support Stronger Forward Expectations
Analysts have modestly raised their price target on Bruker to about $52 from roughly $49, citing constructive bookings trends that help offset the impact of a 2025 guidance cut and support a slightly higher long term growth and valuation outlook. Analyst Commentary Analyst reactions to Bruker reflect a balanced mix of optimism and caution, with modest target price increases and a shift in ratings signaling improving sentiment but also recognition of execution and guidance risks.Anlatı Güncellemesi • Dec 03
BRKR: Constructive Bookings And Rating Upgrades Will Support Stable Forward Expectations
Analysts have modestly increased their price target on Bruker to approximately $49 from about $48, citing constructive bookings despite 2025 guidance cuts and recent upgrades in rating outlook. Analyst Commentary Analyst reactions to Bruker’s updated outlook highlight a more balanced risk and reward profile, with some modest upward revisions to valuation targets despite tempered near term expectations.Analiz Makalesi • Nov 26
Bruker Corporation's (NASDAQ:BRKR) Shares Bounce 26% But Its Business Still Trails The Industry
Bruker Corporation ( NASDAQ:BRKR ) shares have continued their recent momentum with a 26% gain in the last month alone...Anlatı Güncellemesi • Nov 19
BRKR: Booking Momentum Will Improve Sentiment Despite Lowered 2025 Outlook
Analysts have modestly increased their price target for Bruker from $40 to $43, citing more constructive bookings and improved financial metrics, even though 2025 guidance has been lowered. Analyst Commentary Recent analyst updates reflect a complex view of Bruker's prospects, with nuanced shifts in expectations tied to the company's latest financial disclosures and forward guidance.Anlatı Güncellemesi • Nov 03
BRKR: Recent Upgrade Will Drive Confidence In Core Market Resilience
Narrative Update: Bruker Analyst Price Target Increased Analysts have raised Bruker's fair value price target by approximately $1.09 to $47.82, citing improved ratings and updated market assessments, even as growth expectations have moderated slightly. Analyst Commentary Bullish Takeaways Bullish analysts note that the recent price target increase reflects greater confidence in Bruker’s ability to deliver stable financial results in the near term.Anlatı Güncellemesi • Aug 06
Renewed Biopharma Funding And Cost Savings Will Revitalize Markets
Bruker's consensus analyst price target has declined notably, primarily due to weaker revenue growth forecasts and a lower forward P/E multiple, resulting in a reduced fair value estimate of $46.73. What's in the News Bruker provided guidance for FY2025, projecting revenues of $3.43-$3.50 billion (2%-4% reported growth), driven mainly by M&A (3.5%) and FX tailwind (2.5%), but expects 2%-4% organic revenue decline; Q2 2025 revenue is projected to be approximately flat year-over-year at $795-$798 million (Key Developments).Hissedar Getirileri
| BRKR | US Life Sciences | US Pazar | |
|---|---|---|---|
| 7D | 13.4% | 5.0% | 2.2% |
| 1Y | 76.2% | 27.6% | 20.9% |
Getiri vs. Endüstri: BRKR geçen yıl % 27.6 oranında getiri sağlayan US Life Sciences sektörünü aştı.
Getiri vs Piyasa: BRKR geçen yıl % 20.9 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| BRKR volatility | |
|---|---|
| BRKR Average Weekly Movement | 10.3% |
| Life Sciences Industry Average Movement | 8.2% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: BRKR son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: BRKR 'nin haftalık oynaklığı ( 10% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1960 | 11,085 | Frank Laukien | www.bruker.com |
Bruker Corporation, iştirakleriyle birlikte bilimsel aletler ve analitik ve teşhis çözümleri geliştirmekte, üretmekte ve dağıtmaktadır. Şirket dört segmentte faaliyet göstermektedir: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano ve Bruker Energy & Supercon Technologies. Şirket, manyetik rezonans spektroskopisi, klinik öncesi görüntüleme, biyofarma ve uygulamalı, hizmetler ve yaşam döngüsü desteği, entegre veri çözümü ve otomasyon; yaşam bilimleri araçları; yenilikçi nükleer manyetik rezonans (NMR) ve elektron paramanyetik rezonans (EPR) ürünleri; in-vivo süreçler ve ilaç keşfi için çözümler sunmaktadır; satış sonrası çözümler; laboratuvar otomasyonu ve dijitalleştirme çözümleri; kütle spektrometrisi çözümü ve test kitleri, DNA test şeritleri ve floresan tabanlı PCR teknolojileri; genotip ve florotip moleküler tanı kitleri; ve araştırma, analitik ve süreç analizi cihazları ve çözümleri.
Bruker Corporation Temel Bilgiler Özeti
| BRKR temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$8.58b |
| Kazançlar(TTM) | -US$106.90m |
| Gelir(TTM) | US$3.50b |
2.5x
P/S Oranı-81.3x
F/K OranıBRKR aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| BRKR gelir tablosu (TTM) | |
|---|---|
| Gelir | US$3.50b |
| Gelir Maliyeti | US$1.80b |
| Brüt Kâr | US$1.70b |
| Diğer Giderler | US$1.80b |
| Kazançlar | -US$106.90m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -0.70 |
| Brüt Marj | 48.48% |
| Net Kâr Marjı | -3.05% |
| Borç/Özkaynak Oranı | 75.4% |
BRKR uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
0.4%
Mevcut Temettü Verimi-28%
Ödeme OranıŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/11 01:40 |
| Gün Sonu Hisse Fiyatı | 2026/08/11 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Bruker Corporation 32 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |